Global Biotech Wins Queen’s Award for Enterprise
Biocatalysts, a global biotechnology company, has announced it has been named as one of the winners of the Queen’s Awards for Enterprise in Innovation.
In an April 23, 2019 press release, Biocatalysts, a global biotechnology company, has announced it has been named as one of the winners of the Queen’s Awards for Enterprise in Innovation.
The Queen’s Awards for Enterprise are announced annually and are granted to United Kingdom businesses deemed to have demonstrated ‘outstanding achievement’ in the fields of innovation, international trade, sustainable development, and promoting opportunity through social mobility.
Biocatalysts has been granted an award in recognition of its approach to providing enzyme solutions to its customers. Specifically, the company has been recognized for its MetXtra bespoke software system, which is capable of screening millions of sequences to identify new enzymes in hours.
Rod Sears-Black, Biocatalysts’ managing director, commented in the release, “We are very proud to receive the Queen’s award for Innovation. It recognizes the dedication and commitment of the Biocatalysts team to create this unique offering to the market.”
Source: Biocatalysts
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
August 5th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
